TerminatedPhase 2NCT04925947

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

Studying Thymic carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Weill Medical College of Cornell University
Principal Investigator
Barbara Ma, MD
Weill Medical College of Cornell University
Intervention
KN046(drug)
Enrollment
4 enrolled
Eligibility
18 years · All sexes
Timeline
2021 – 2023

Study locations (1)

Collaborators

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04925947 on ClinicalTrials.gov

Other trials for Thymic carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Thymic carcinoma →

← Back to all trials